1953-2023. Seventy Years of the Nerve Growth Factor: A Potential Novel Treatment in Neurological Diseases?
aging and disease · 2024
DOI: 10.14336/ad.2024.0573 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift aging and disease, 2024. Verfasst von Davide Norata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Università Campus Bio-Medico di Roma, Via Alvaro…. Hauptthemen laut MEDLINE: Nerve Growth Factor, Nervous System Diseases. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Rita Levi-Montalcini's 1953 discovery of nerve growth factor (NGF) in mouse sarcoma tumors marked a groundbreaking moment in neuroscience. NGF, a key signaling molecule, became the first identified neurotrophic factor, influencing the growth, differentiation, and survival of neurons in both peripheral and central nervous systems. NGF and related neurotrophic factors hold therapeutic potential for various neurological disorders, such as Alzheimer's Disease, Parkinson's Disease, Huntington's Disease, amyotrophic lateral sclerosis, spinal cord injuries, neuropathies, traumatic brain injuries, and stroke. However, despite promising in vitro studies and animal models findings, NGF efficacy in patients remains unproven. Indeed, its use as a therapeutic agent faces challenges in delivery and clinical translation. This review delves into these challenges, exploring ongoing research on refined delivery methods, dosages, and safety profiles. Innovative strategies, including molecular mimicking, combination therapies, gene therapy, and coupling with neuromodulation techniques like transcranial magnetic stimulation and vagal nerve stimulation, are discussed. Incorporating nerve growth factor (NGF) into a comprehensive strategy may prove beneficial, particularly in non-neurodegenerative conditions such as stroke, trauma, and neuropathies. In these instances, NGF holds promise for promoting tissue regeneration and repair. Challenges persist in addressing the complexity of neurodegenerative pathologies for a combined therapeutic approach.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Unit of Neurology, Neurophysiology, Neurobiology and Psychiatry, Università Campus Bio-Medico di Roma, Via Alvaro del Portillo, 21 - 00128 Roma, Italy.
- Fondazione Policlinico Universitario Campus Bio-Medico, Via Alvaro del Portillo, 200 - 00128 Rome, Italy.
- Radiology and Neuroradiology Unit, Department of Imaging, Radiation Therapy and Hematology, Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario Agostino Gemelli, Istituto di Ricovero e Cura a Cara…
- Dompé Farmaceutici S.p.A., Via Campo di Pile -67100 L'Aquila, Italy.
Zitieren
APA
Norata, D., Capone, F., Motolese, F., Marano, M., Rossi, M., Calandrelli, R., Sacchetti, M., Mantelli, F., Di Lazzaro, V., & Pilato, F. (2024). 1953-2023. Seventy Years of the Nerve Growth Factor: A Potential Novel Treatment in Neurological Diseases?. aging and disease. https://doi.org/10.14336/ad.2024.0573
Vancouver
Norata D, Capone F, Motolese F, Marano M, Rossi M, Calandrelli R, et al. 1953-2023. Seventy Years of the Nerve Growth Factor: A Potential Novel Treatment in Neurological Diseases?. aging and disease. 2024. doi:10.14336/ad.2024.0573
BibTeX
@article{Norata2024,
author = {Norata, Davide and Capone, Fioravante and Motolese, Francesco and Marano, Massimo and Rossi, Mariagrazia and Calandrelli, Rosalinda and Sacchetti, Marta and Mantelli, Flavio and Di Lazzaro, Vincenzo and Pilato, Fabio},
title = {1953-2023. Seventy Years of the Nerve Growth Factor: A Potential Novel Treatment in Neurological Diseases?},
journal = {aging and disease},
year = {2024},
doi = {10.14336/ad.2024.0573}
}
EUVIMED